Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection

The prenylation inhibitor lonafarnib (LNF) is a potent antiviral agent providing a breakthrough for the treatment of hepatitis delta virus (HDV). The current study used a maximum likelihood approach to model LNF pharmacokinetic (PK) and pharmacodynamic (PD) parameters and predict the dose needed to...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Hepatol Commun
Asıl Yazarlar: Canini, Laetitia, Koh, Christopher, Cotler, Scott J., Uprichard, Susan L., Winters, Mark A., Han, Ma Ai Thanda, Kleiner, David E., Idilman, Ramazan, Yurdaydin, Cihan, Glenn, Jeffrey S., Heller, Theo, Dahari, Harel
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2017
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5721397/
https://ncbi.nlm.nih.gov/pubmed/29404459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep4.1043
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller